CoLucid Pharmaceuticals, Inc.
CLCD
CLCD was delisted on the 28th of February, 2017.
20 hedge funds and large institutions have $21.4M invested in CoLucid Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
11% more funds holding
Funds holding: 18 → 20 (+2)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
56% less capital invested
Capital invested by funds: $49.2M → $21.4M (-$27.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$608K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$191K |
| 3 |
Goldman Sachs
New York
|
+$110K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$94K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$85.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$568K |
| 2 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
-$275K |
| 3 |
Millennium Management
New York
|
-$211K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$44K |
| 5 |
Morgan Stanley
New York
|
-$43.7K |
CLCD Hedge Fund Activity: Q3 2015 in Review
20 of the 3,583 institutional investors tracked by Wall St. Rank reported a position in CoLucid Pharmaceuticals, Inc. (CLCD) for Q3 2015, worth a combined $21.4M — down 56% from $49.2M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CLCD positions and 1 closed out — a net gain of 3 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $608K. The largest seller was Pentwater Capital Management, cutting an estimated $568K.
- 20 institutional investors held CoLucid Pharmaceuticals, Inc. (CLCD) as of Q3 2015, up from 18 in Q2 2015.
- Funds reported $21.4M of CoLucid Pharmaceuticals, Inc. stock for Q3 2015, down 56% quarter-over-quarter.
- 4 funds opened new CoLucid Pharmaceuticals, Inc. positions in Q3 2015 and 1 closed out, a net change of +3 holders.
- The largest CoLucid Pharmaceuticals, Inc. buyer in Q3 2015 was T. Rowe Price Associates, an estimated $608K added.
- The largest CoLucid Pharmaceuticals, Inc. seller in Q3 2015 was Pentwater Capital Management, an estimated $568K sold.
Based on aggregated 13F filings for Q3 2015.